Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

Pitt Street Research sees strong upside in Prescient Therapeutics as one of the most advanced oncology companies on the ASX .

As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

The rate of COVID-related intensive care unit (ICU) admissions was 9.2 per 1,000 person-years among patients who received a monovalent booster and 13.3 per 1,000 person-years for patients who ...

At 9 current students and 24 graduates, the growing MD-PhD program is a unicorn of sorts at the University of Mississippi ...

Pharvaris' innovative approach to treating hereditary angioedema (HAE) with deucrictibant. Read here for an investment ...

The new Blueprint for Patient-Centered Value Research offers a roadmap for embedding patient voices throughout every stage of ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without ...